The aldosterone-renin screening market is forecasted to grow from USD 574.8 million in 2025 to USD 1,109.7 million by 2035, at a CAGR of 6.8% during the forecast period. The aldosterone-renin ...

First- and second-generation potassium binders reduced potassium levels in a Swedish cohort of patients, despite premature ...

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

With its demonstrated clinical benefits and superior selectivity profile, SC0062 is positioned to potentially become a ...

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Both cortisol and aldosterone are potent activators of renal MCRs. In vitro, cortisol is a tenfold more potent activator of the MCR than aldosterone. In the kidney, 11β-hydroxysteroid ...

While heart disease has been the leading cause of death in the U.S. for over a century, the past 50 years have seen a ...

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 2 ...

The FDA has approved Widaplik (telmisartan, amlodipine and indapamide) for the treatment of hypertension, including as initial treatment, to lower blood pressure.

Discover how dehydration silently destroys kidney function. Learn the hidden dangers of chronic water shortage and protect ...

Hypertension treatment and the role of cortisol in cardio-renal-metabolic health were among the featured topics from this ...